Physician profile
Brian Bui
NPI 1316553688
$5,038.52
in general payments reported to CMS, 2019-2025
13 companies · $572 in 2025
The $572 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $628 · 2022: $2,231 · 2023: $1,353 · 2024: $255 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,714 · Travel and Lodging: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.61 |
| Travel and Lodging | $466.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,002.31 | 2022-2025 | Total30, Precision 1, Dailies Total1 |
| Coopervision INC. | $833.56 | 2023-2025 | Misight Contact Lens, Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $547.77 | 2021-2025 | |
| Bausch & Lomb Americas INC. | $434.50 | 2022-2025 | Infuse |
| Abbvie INC. | $285.15 | 2022 | |
| Sun Pharmaceutical Industries INC. | $250.98 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $212.09 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $124.99 | 2021 | |
| Dompe US, INC. | $124.97 | 2023 | Oxervate |
| Optos, INC. | $93.75 | 2021 | |
| Glaukos Corporation | $81.42 | 2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Allergan, INC. | $29.29 | 2021 | |
| Kala Pharmaceuticals, INC. | $17.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.